BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueda H. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. Pain Manag 2020;10:43-53. [PMID: 31852400 DOI: 10.2217/pmt-2019-0036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gonzalez PA, Simcox J, Raff H, Wade G, Von Bank H, Weisman S, Hainsworth K. Lipid signatures of chronic pain in female adolescents with and without obesity. Lipids Health Dis 2022;21:80. [PMID: 36042489 DOI: 10.1186/s12944-022-01690-2] [Reference Citation Analysis]
2 Akhilesh, Uniyal A, Gadepalli A, Tiwari V, Allani M, Chouhan D, Ummadisetty O, Verma N, Tiwari V. Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain. Life Sci 2022;288:120187. [PMID: 34856209 DOI: 10.1016/j.lfs.2021.120187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Gaire BP, Choi JW. Critical Roles of Lysophospholipid Receptors in Activation of Neuroglia and Their Neuroinflammatory Responses. Int J Mol Sci 2021;22:7864. [PMID: 34360625 DOI: 10.3390/ijms22157864] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki J, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep 2021;11:3984. [PMID: 33597645 DOI: 10.1038/s41598-021-83569-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Oehler B, Brack A, Blum R, Rittner HL. Pain Control by Targeting Oxidized Phospholipids: Functions, Mechanisms, Perspectives. Front Endocrinol (Lausanne) 2020;11:613868. [PMID: 33569042 DOI: 10.3389/fendo.2020.613868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Arun P, Rossetti F, DeMar JC, Wang Y, Batuure AB, Wilder DM, Gist ID, Morris AJ, Sabbadini RA, Long JB. Antibodies Against Lysophosphatidic Acid Protect Against Blast-Induced Ocular Injuries. Front Neurol 2020;11:611816. [PMID: 33384658 DOI: 10.3389/fneur.2020.611816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ueda H. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog Lipid Res 2021;81:101079. [PMID: 33259854 DOI: 10.1016/j.plipres.2020.101079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
8 Dormer L. Welcome to the 11th Volume of Pain Management. Pain Manag 2021;11:1-3. [PMID: 33234002 DOI: 10.2217/pmt-2020-0093] [Reference Citation Analysis]
9 Gaire BP, Sapkota A, Choi JW. BMS-986020, a Specific LPA1 Antagonist, Provides Neuroprotection against Ischemic Stroke in Mice. Antioxidants (Basel) 2020;9:E1097. [PMID: 33171697 DOI: 10.3390/antiox9111097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jangde N, Ray R, Rai V. RAGE and its ligands: from pathogenesis to therapeutics. Crit Rev Biochem Mol Biol 2020;55:555-75. [PMID: 32933340 DOI: 10.1080/10409238.2020.1819194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Harwood J, Lloyd-evans E, Hemmings D, Brindley D. Signalling by lysophosphatidate and its health implications. Essays in Biochemistry 2020;64:547-63. [DOI: 10.1042/ebc20190088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]